Project Period: 12 months from funding date
Grant Award: Up to $15,000
Project initiation: April 2023
● Perform meta-analyses to generalize novel pharmacogenetic association(s) of key clinical relevance ( pharmacokinetic, toxicity, or efficacy phenotypes).
● Model the effects of multiple variants/genes on a pharmacokinetic or treatment outcome in vitro.
● Determine the effect of genetics-guided treatment on a pharmacokinetic, toxicity or efficacy outcome from an existing dataset.
● Validate emerging pharmacogenetic associations in an independent patient cohort with similar treatment and clinical endpoints.
● Mechanistically validate pharmacogenetic associations using experimental model systems or human samples (e.g., cellular models, animal studies or plasma markers).
Proposals that include international collaboration and participants from diverse and understudied populations will be prioritized. Proposals that require patient, data, or sample collection are acceptable, but will require compelling evidence of feasibility of completing collection within the grant timeframe.
Proposals will be reviewed on the basis of scientific merit and significance, strength of the collaborative effort, qualifications of the investigator team and the potential for future funding. It is anticipated that two grants of $15,000 each will be awarded this year. The funding can be used for a variety of purposes, but is expected to be used to assist individuals in efforts to collect, clean, merge, and analyze the existing data. Funding for additional genotyping in pharmacogenetic validation studies, for example, is acceptable.
PI(s) must be PGRN members. An individual can be listed as a PI or MPI on only one proposal to the PGRN Research Collaboration Grant. Prior PGRN Research Collaboration Grant awardees (PI or MPIs only) are not eligible to serve as a PI or MPI in a new application. Trainees are eligible with faculty sponsorship documented in a letter of support.
The following sections should be included in your proposal. Applicants have flexibility in the organization but all sections are required.
1. Introduction to the proposal – for resubmissions only, an additional ½ page will be allowed to summarize modifications made in response to the prior review. The total proposal page limit for resubmissions is 4 ½ pages.
2. Aims – no more than 1 page
3. Background and significance
4. Collaborative team – including description of investigators and data use agreements
5. Research strategy and approach – Include statistical analysis. Studies focused on diverse and understudied populations are encouraged.
6. Description of data sharing plan and agreements with milestones
7. Timeline – project completion is expected 12 months after the initial award. A 6 month no cost extension may be requested with appropriate justification.
Budget and justification (half page)
Provide a detailed budget and justification that will be considered in the review. Budgets should be realistic and any additional funds available to contribute to the project should be discussed. Equipment is allowed if well justified. Indirect costs are not allowed. If institutions mandate indirect funding, please reach out to the grants administrator for further discussion (firstname.lastname@example.org).
Criteria for Review
Proposals will be reviewed by a Grant Review Committee composed of PGRN members with appropriate expertise. Scorable criteria include significance, study design and analysis, strength of collaborations, inclusion of diverse and understudied populations, feasibility of completion during funding period, and potential for future funding. Each proposal will be reviewed by at least two reviewers and scores will be reviewed for prioritization for funding by the entire review panel. Reviewer comments will be shared with all applicants after the final funding decision. The final selection for funding will be made by the PGRN Executive Council.
The awardee(s) is expected to present their results during the PGRN Research in Progress seminar series and/or the PGRN annual meeting within 1 year after the end of the funding period. Genetic data generated through this project must be desposited into a publicly accessible database such as dbGAP. If data deposition is not possible, please contact the grants administrator for further discussion (email@example.com).
HOW TO APPLY
Combine the Proposal, Budget and CV's of PI collaborators, references into a single .pdf
Send as an attachment to: firstname.lastname@example.org
Deadline: Midnight (EST) on January 3, 2023
Characterization of Cohorts/Phenotypes Available for Collaborative Studies
Please fill out information about cohorts you have access to and would be willing to collaborate on for this or future projects. Responses to columns are optional, but please fill in as much information as you can because this will allow better understanding of the collaborative opportunities. You may fill in more than one line if you have more than one disease area that can be studied using a cohort.